Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ATOP TRIAL: Adjuvant Ado-Trastuzumab Emtansine (T-DM1) for Older Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Next Previous
Trial Profile

ATOP TRIAL: Adjuvant Ado-Trastuzumab Emtansine (T-DM1) for Older Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trastuzumab emtansine (Primary)
  • Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer; Male breast cancer
  • Focus Therapeutic Use
  • Acronyms ATOP TRIAL

Most Recent Events

  • 17 Feb 2026 Planned End Date changed from 30 Aug 2029 to 30 Aug 2027.
  • 04 Dec 2025 According to Dana-Farber Cancer Institute media release, data from the trial will be presented at the 48th annual San Antonio Breast Cancer Symposium, December 9-12.
  • 10 Jan 2022 Planned End Date changed from 31 Jan 2025 to 30 Aug 2029.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top